Month: June 2018

  • MIFTEC and US Nuclear Join Race to Fill $7 Billion/Year Shortage of Medical Isotopes

    MIFTEC and US Nuclear Join Race to Fill $7 Billion/Year Shortage of Medical Isotopes

    Los Angeles, CA. June 5, 2018—US Nuclear Corp (OTCBB: UCLE) and MIFTEC recently signed a definitive agreement which formally appoints US Nuclear as the exclusive manufacturer of MIFTEC’s revolutionary medical isotope generators for North America and Asia, and makes US Nuclear a sales representative for all MIFTEC products. This definitive agreement replaces the Letter of Intent signed back in December 2017. MIFTEC’s parent company, MIFTI Nuclear Fusion, is a leader in developing fusion power and has shown that their staged Z-pinch fusion technique produces high neutron flux which can be used to produce medical isotopes at a fraction of the cost of current methods.

    US Nuclear (OTCMKTS:UCLE) Has Become Investor’s Preferred Choice

    There are two main uses for medical isotopes: diagnosis and treatment. Diagnostic procedures using radioisotopes are now routine, and can be used to examine blood flow to the brain, functioning of the liver, lungs, heart, or kidneys—the advantage over other techniques being that you can image both bone and soft tissue, and assess what is happening physiologically. The most prominent treatment application is for cancer, using radiation to weaken or destroy targeted cancer cells.

    (more…)